BACKGROUND: Severe 5-FU toxicity in adjuvant therapy of colorectal cancer may require change of therapy. We retrospectively explored the safety and efficacy of adjuvant raltitrexed in patients intolerant of 5-FU. METHODS: Over a 5 year period, patients who received 5-FU and subsequent raltitrexed therapy were identified. RESULTS: There were 44 patients, (39 stage III). Median number of prior 5-FU cycles was 2. Three year relapse free and overall survival proportions for stage III patients were 70.8% and 83.6%, respectively. CONCLUSIONS: Raltitrexed adjuvant therapy can be given safely and effectively in patients where further 5-FU is contraindicated.
BACKGROUND: Severe 5-FUtoxicity in adjuvant therapy of colorectal cancer may require change of therapy. We retrospectively explored the safety and efficacy of adjuvant raltitrexed in patients intolerant of 5-FU. METHODS: Over a 5 year period, patients who received 5-FU and subsequent raltitrexed therapy were identified. RESULTS: There were 44 patients, (39 stage III). Median number of prior 5-FU cycles was 2. Three year relapse free and overall survival proportions for stage III patients were 70.8% and 83.6%, respectively. CONCLUSIONS:Raltitrexed adjuvant therapy can be given safely and effectively in patients where further 5-FU is contraindicated.
Authors: Daniel I G Cubero; Felipe Melo Cruz; Patrícia Santi; Ismael Dale C G Silva; Auro Del Giglio Journal: Ther Adv Med Oncol Date: 2012-07 Impact factor: 8.168
Authors: Anna Tochowicz; Sean Dalziel; Oliv Eidam; Joseph D O'Connell; Sarah Griner; Janet S Finer-Moore; Robert M Stroud Journal: J Med Chem Date: 2013-06-21 Impact factor: 7.446